drugset / Trial / NCT06170710
Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC
RandomizedParallel-groupOpen-labelTreatment
Summary
This trial aims to evaluate whether the addition of anti-PD-1 antibody to adjuvant postoperative chemoradiotherapy could improve disease free survival in patients with high-risk locally advanced head and neck squamous cell carcinoma (HNSCC).
Timeline
- Start
- 2023-12-01
- Primary completion
- 2025-11-30
- Completion
- 2027-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | — |
| Subject | Nivolumab | Monoclonal antibody | 3 mg/kg | — |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | — |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | — |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | — |
| Subject | Toripalimab | Monoclonal antibody | 240 mg | — |